Wang et al. demonstrated the efficacy of TSN in vivo in SW480 xenografted nude mice by injecting TSN (0.15, 0.3 mg/kg) for 14 consecutive days in the absence of a positive control group, with daily intraperitoneal injections of 0.15/0.30 mg/kg significantly inhibiting tumor growth (p < 0.01), and reductions in tumor weight and volume correlating with reduced nuclear localization and upregulation of GSK-3β expression in β-catenin. The gene discussed is GSK3B; the disease is neoplasm.